Trial Protocol ID
USOR 24100_FTH-PIK-201

Investigator
Danubia Hester, MD

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel, and a Substudy Evaluating PIKTOR with Paclitaxel plus an Insulin-Suppressing Diet, in Patients with Advanced or Recurrent Endometrial Cancer (FTH-PIK-201)

Trial Protocol ID
STRO-002-GM3 *RIT*

***REFERRAL ONLY*** REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

Trial Protocol ID
USOR 24112_ TORL123-002

Investigator
Carol Tweed, MD

A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (CLND6) (TORL123-002)

Trial Protocol ID
USOR 21270_ZN-c3-005 *RIT* on HOLD effective 09/20/2024

Investigator
Syed Shahid Mahmood, MD

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial Protocol ID
USOR 21271_ZN-c3-004 | GOG 3065

Investigator
Jeanine L Werner, MD

A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 | GOG 3065)